SPO Medical Retains American Capital Ventures for Investor Relations Services

NEW YORK, April 17 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC:
SPOM), a leading developer of biosensor and microprocessor technologies for
use in portable monitoring devices, today announced that it has retained the
services of American Capital Ventures (ACV), a leading provider of
comprehensive investor relations services to the small cap community, as an
investor relations consultant.
Michael Braunold, President and Chief Executive Officer of SPO Medical
commented, "As we continue to grow our revenues and enhance our distribution
base, it has become increasingly important to reach out to the investment
community. Our goal is to inform current and prospective investors of our
financial prospects and the value proposition offered by our product pipeline
and strategy." Mr. Braunold continued, "Our portable devices and new consumer
applications will appeal to an ever growing number of markets globally. This
is a powerful message we need to convey to investors and American Capital
Ventures has a proven track record assisting small cap companies in
communicating their message to the investor community."
Howard Gostfrand, President of American Capital Ventures, commented, "SPO
Medical has positioned itself well in the burgeoning medical field of
non-invasive devices. They have clearly laid the groundwork with key
investments and strategic partnerships that have been delivering tangible
results. Achieving revenues of $5 million in 2007 after only three years, and
with an impressive product channel, SPOM is a perfect example of a promising
undiscovered small cap company worth an investor's consideration."
About SPO Medical
SPO Medical (SPOM) is a leading developer of biosensor and microprocessor
technologies for use in portable monitoring devices to capture life-saving
and life-enhancing information within four key markets: medical care; home
and remote-care; sports and wellness; and safety and security. Its patented
technology uses information gathered from the reflectance of light on the
human blood stream, in a non-invasive manner, to monitor key vital signs. The
Company distributes its products through a network of distributors and also
licenses its technologies to appropriate client corporations for
commercialization and distribution. For more information, visit
http://www.spomedical.com.
About American Capital Ventures (ACV)
American Capital Ventures (ACV) is a boutique investor relations firm
founded on the principals of hard work, professionalism and integrity. Our
company offers emerging growth companies a different, more comprehensive
approach to investor relations. ACV delivers highly effective investor
communications counsel in conjunction with developing tangible brokerage
relationships for our clients. Our unique blend of creating awareness while
effectively increasing a company's trading volume has allowed us to
continually expand our business. Our goal is to allow management the ability
to focus on their core business, while assisting them in communicating their
message and develop their investor relationships.
This press release contains forward-looking statements that involve
substantial uncertainties and risks. These forward-looking statements are
based upon our current expectations, estimates and projections about our
business and our industry, and that reflect our beliefs and assumptions based
upon information available to us at the date of this release. We caution
readers that forward-looking statements are predictions based on our current
expectations about future events. These forward-looking statements are not
guarantees of future performance and are subject to risks, uncertainties and
assumptions that are difficult to predict. Our actual results, performance or
achievements could differ materially from those expressed or implied by the
forward-looking statements as a result of a number of factors, including but
not limited to, changes in economic conditions generally and the medical
devices market specifically, changes in technology, legislative or regulatory
changes that affect us, the availability of working capital, the introduction
of competing products, market acceptance of our new products, changes in our
operating strategy or development plans and the risks and uncertainties
discussed under the heading "Risk Factors" in Item 1 of our Annual Report on
Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no
obligation to revise or update any forward-looking statement for any reason.
SPO Medical Contact:

Michael Braunold, President & CEO,
investors@spomedical.com ,
+1-805-823-8163;

ACV Contact:

Howard Gostfrand / David Sasso,
+1-305-918-7000,
info@amcapventures.com .

http://www.amcapventures.com

SOURCE SPO Medical Inc

SPO Medical Contact: Michael Braunold, President & CEO,
investors@spomedical.com , +1-805-823-8163; ACV Contact: Howard Gostfrand /
David Sasso, +1-305-918-7000, info@amcapventures.com .